Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Nuvo Research's investigational new drug (IND) application for Lidocaine Spray formulation (NRI-ANA).
Subscribe to our email newsletter
The FDA has also given permission for commencing Phase 1 trials with NRI-ANA as a treatment for an acute neuropathic pain condition using molecular skin penetration enhancers identified by Nuvo scientists.
The drug is delivered via transdermal carriers directly to the site of pain, offering site-specific pain therapy while limiting systemic exposure for reducing adverse events, negative side effects and potential drug-drug interactions.